Up‐dosing of nivolumab may induce serious immune‐related adverse events
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.17701
Abstract: Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or 240 mg/body every two-three weeks… read more here.
Keywords: serious immune; may induce; induce serious; immune related ... See more keywords